Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|July 25, 2022
EMA Recommends Eleven New Medicines
Author(s)Pharmaceutical Technology Editors
The agency’s human medicines committee recommended drugs to treat breast cancer, lupus nephritis, type 2 diabetes and more.
Advertisement
The European Medicines Agency (EMA) announced on July 22, 2022 that its Committee for Medicinal Products for Human Use (CHMP) recommended approval for 11 medicines at its July 2022 meeting. The medicines treat a variety of conditions including cancer and type 2 diabetes.
The approved medicines included the following:
- Celdoxome pegylated liposomal (doxorubicin hydrochloride) was approved for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma, and Kaposi's sarcoma.
- Lupkynis (voclosporin) was approved to treat lupus nephritis, which is a condition caused by lupus where the kidneys are inflamed.
- Mounjaro (tirzepatide) was approved for the treatment of adults with type 2 diabetes mellitus.
- Opdualag (relatlimab/nivolumab) was approved to treat melanoma that has spread to other parts of the body and cannot be removed by surgery.
- Tezspire (Tezepelumab) was approved as an add-on treatment in adult and adolescent patients with severe asthma.
- Vabysmo (faricimab) was approved for the treatment of neovascular age-related macular degeneration and visual impairment due to diabetic macular edema in adults.
- Thalidomide Lipomed (thalidomide) received a positive opinion for the treatment of multiple myeloma.
The CHMP also granted conditional marketing authorization for Tecvayli (teclistamab) for the treatment of adults with relapsed and refractory multiple myeloma, who have received at least three prior therapies. Tecvayli was processed through EMA’s PRIority MEdicines scheme, which provides early scientific and regulatory support for drugs that treat unmet needs.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement